Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

Tony S. Mok; Yi Long Wu; Myung Ju Ahn; Marina C. Garassino; Hye Ryoun Kim; Suresh S. Ramalingam; Frances A. Shepherd; Yong He; Hiroaki Akamatsu; Willemijn S. M. E. Theelen; Chee K. Lee; Martin Sebastian; Alison Templeton; Helen Mann; Marcelo Marotti; Serban Ghiorghiu; Vassiliki A. Papadimitrakopoulou

doi:10.1056/NEJMoa1612674

Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

Tony S. Mok, Yi Long Wu, Myung Ju Ahn, Marina C. Garassino, Hye Ryoun Kim, Suresh S. Ramalingam, Frances A. Shepherd, Yong He, Hiroaki Akamatsu, Willemijn S. M. E. Theelen, Chee K. Lee, Martin Sebastian, Alison Templeton, Helen Mann, Marcelo Marotti, Serban Ghiorghiu, Vassiliki A. Papadimitrakopoulou

Fondazione IRCCS Istituto Nazionale dei Tumori

Research output: Contribution to journal › Article › peer-review

Abstract

Background Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that is selective for both EGFR-TKI sensitizing and T790M resistance mutations in patients with non-small-cell lung cancer. The efficacy of osimertinib as compared with platinum-based therapy plus pemetrexed in such patients is unknown. Methods In this randomized, international, open-label, phase 3 trial, we assigned 419 patients with T790M-positive advanced non-small-cell lung cancer, who had disease progression after first-line EGFR-TKI therapy, in a 2:1 ratio to receive either oral osimertinib (at a dose of 80 mg once daily) or intravenous pemetrexed (500 mg per square meter of body-surface area) plus either carboplatin (target area under the curve, 5 [AUC5]) or cisplatin (75 mg per square meter) every 3 weeks for up to six cycles; maintenance pemetrexed was allowed. In all the patients, disease had progressed during receipt of first-line

Original language	Undefined/Unknown
Pages (from-to)	629-640
Number of pages	12
Journal	New England Journal of Medicine
Volume	376
Issue number	7
DOIs	https://doi.org/10.1056/NEJMoa1612674
Publication status	Published - Feb 1 2017

Keywords

Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use, Carcinoma, Non-Small-Cell Lung/*drug therapy, Disease-Free Survival, Female, Humans, Lung Neoplasms/*drug therapy, Male, Middle Aged, Mutation, Pemetrexed/*administration dosage/adverse effects, Piperazines/*administration dosage/adverse effects, Platinum/administration dosage, Receptor, Epidermal Growth Factor/*antagonists inhibitors, Young Adult

Access to Document

10.1056/NEJMoa1612674

Cite this

Mok, T. S., Wu, Y. L., Ahn, M. J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., Lee, C. K., Sebastian, M., Templeton, A., Mann, H., Marotti, M., Ghiorghiu, S., & Papadimitrakopoulou, V. A. (2017). Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. New England Journal of Medicine, 376(7), 629-640. https://doi.org/10.1056/NEJMoa1612674

Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. / Mok, Tony S.; Wu, Yi Long; Ahn, Myung Ju; Garassino, Marina C.; Kim, Hye Ryoun; Ramalingam, Suresh S.; Shepherd, Frances A.; He, Yong; Akamatsu, Hiroaki; Theelen, Willemijn S. M. E.; Lee, Chee K.; Sebastian, Martin; Templeton, Alison; Mann, Helen; Marotti, Marcelo; Ghiorghiu, Serban; Papadimitrakopoulou, Vassiliki A.

In: New England Journal of Medicine, Vol. 376, No. 7, 01.02.2017, p. 629-640.

Research output: Contribution to journal › Article › peer-review

Mok, TS, Wu, YL, Ahn, MJ, Garassino, MC, Kim, HR, Ramalingam, SS, Shepherd, FA, He, Y, Akamatsu, H, Theelen, WSME, Lee, CK, Sebastian, M, Templeton, A, Mann, H, Marotti, M, Ghiorghiu, S & Papadimitrakopoulou, VA 2017, 'Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.', New England Journal of Medicine, vol. 376, no. 7, pp. 629-640. https://doi.org/10.1056/NEJMoa1612674

Mok, Tony S. ; Wu, Yi Long ; Ahn, Myung Ju ; Garassino, Marina C. ; Kim, Hye Ryoun ; Ramalingam, Suresh S. ; Shepherd, Frances A. ; He, Yong ; Akamatsu, Hiroaki ; Theelen, Willemijn S. M. E. ; Lee, Chee K. ; Sebastian, Martin ; Templeton, Alison ; Mann, Helen ; Marotti, Marcelo ; Ghiorghiu, Serban ; Papadimitrakopoulou, Vassiliki A. / Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. In: New England Journal of Medicine. 2017 ; Vol. 376, No. 7. pp. 629-640.

@article{6577034f9f0441a9b01fdb182c8151b9,

title = "Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.",

abstract = "Background Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that is selective for both EGFR-TKI sensitizing and T790M resistance mutations in patients with non-small-cell lung cancer. The efficacy of osimertinib as compared with platinum-based therapy plus pemetrexed in such patients is unknown. Methods In this randomized, international, open-label, phase 3 trial, we assigned 419 patients with T790M-positive advanced non-small-cell lung cancer, who had disease progression after first-line EGFR-TKI therapy, in a 2:1 ratio to receive either oral osimertinib (at a dose of 80 mg once daily) or intravenous pemetrexed (500 mg per square meter of body-surface area) plus either carboplatin (target area under the curve, 5 [AUC5]) or cisplatin (75 mg per square meter) every 3 weeks for up to six cycles; maintenance pemetrexed was allowed. In all the patients, disease had progressed during receipt of first-line",

keywords = "Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use, Carcinoma, Non-Small-Cell Lung/*drug therapy, Disease-Free Survival, Female, Humans, Lung Neoplasms/*drug therapy, Male, Middle Aged, Mutation, Pemetrexed/*administration dosage/adverse effects, Piperazines/*administration dosage/adverse effects, Platinum/administration dosage, Receptor, Epidermal Growth Factor/*antagonists inhibitors, Young Adult",

author = "Mok, {Tony S.} and Wu, {Yi Long} and Ahn, {Myung Ju} and Garassino, {Marina C.} and Kim, {Hye Ryoun} and Ramalingam, {Suresh S.} and Shepherd, {Frances A.} and Yong He and Hiroaki Akamatsu and Theelen, {Willemijn S. M. E.} and Lee, {Chee K.} and Martin Sebastian and Alison Templeton and Helen Mann and Marcelo Marotti and Serban Ghiorghiu and Papadimitrakopoulou, {Vassiliki A.}",

year = "2017",

month = feb,

day = "1",

doi = "10.1056/NEJMoa1612674",

language = "Non definita",

volume = "376",

pages = "629--640",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "7",

}

TY - JOUR

T1 - Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

AU - Mok, Tony S.

AU - Wu, Yi Long

AU - Ahn, Myung Ju

AU - Garassino, Marina C.

AU - Kim, Hye Ryoun

AU - Ramalingam, Suresh S.

AU - Shepherd, Frances A.

AU - He, Yong

AU - Akamatsu, Hiroaki

AU - Theelen, Willemijn S. M. E.

AU - Lee, Chee K.

AU - Sebastian, Martin

AU - Templeton, Alison

AU - Mann, Helen

AU - Marotti, Marcelo

AU - Ghiorghiu, Serban

AU - Papadimitrakopoulou, Vassiliki A.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Background Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that is selective for both EGFR-TKI sensitizing and T790M resistance mutations in patients with non-small-cell lung cancer. The efficacy of osimertinib as compared with platinum-based therapy plus pemetrexed in such patients is unknown. Methods In this randomized, international, open-label, phase 3 trial, we assigned 419 patients with T790M-positive advanced non-small-cell lung cancer, who had disease progression after first-line EGFR-TKI therapy, in a 2:1 ratio to receive either oral osimertinib (at a dose of 80 mg once daily) or intravenous pemetrexed (500 mg per square meter of body-surface area) plus either carboplatin (target area under the curve, 5 [AUC5]) or cisplatin (75 mg per square meter) every 3 weeks for up to six cycles; maintenance pemetrexed was allowed. In all the patients, disease had progressed during receipt of first-line

AB - Background Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that is selective for both EGFR-TKI sensitizing and T790M resistance mutations in patients with non-small-cell lung cancer. The efficacy of osimertinib as compared with platinum-based therapy plus pemetrexed in such patients is unknown. Methods In this randomized, international, open-label, phase 3 trial, we assigned 419 patients with T790M-positive advanced non-small-cell lung cancer, who had disease progression after first-line EGFR-TKI therapy, in a 2:1 ratio to receive either oral osimertinib (at a dose of 80 mg once daily) or intravenous pemetrexed (500 mg per square meter of body-surface area) plus either carboplatin (target area under the curve, 5 [AUC5]) or cisplatin (75 mg per square meter) every 3 weeks for up to six cycles; maintenance pemetrexed was allowed. In all the patients, disease had progressed during receipt of first-line

KW - Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use, Carcinoma, Non-Small-Cell Lung/drug therapy, Disease-Free Survival, Female, Humans, Lung Neoplasms/drug therapy, Male, Middle Aged, Mutation, P

U2 - 10.1056/NEJMoa1612674

DO - 10.1056/NEJMoa1612674

M3 - Articolo

VL - 376

SP - 629

EP - 640

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 7

ER -